Hims & Hers Prepares Legal Peptides Amidst FDA Scrutiny

Hims & Hers Health plans to introduce legally available peptides in 2026, a move met with cautious optimism by investors. Despite the burgeoning popularity of peptide treatments for various health and anti-aging purposes, industry experts suggest that sales from these offerings are unlikely to drive significant revenue growth in the current year. The U.S. peptide market is estimated to be worth between $2.2 billion and $3.3 billion, with demand rising after the FDA began its review process in April.

CEO Andrew Dudum announced that Hims will begin selling currently legal peptides, such as NAD+, sermorelin, and glutathione, by the end of this year. These compounds support metabolic function, weight loss, and immune health. However, analysts note that because NAD+ is already widely available, its impact on revenue will be less substantial compared to peptides awaiting FDA approval.

Hims also possesses a significant advantage through its ownership of a popular U.S. compounding pharmacy, enabling in-house manufacturing. The company is conducting testing for BPC-157, a peptide used for tissue repair that is currently under FDA review. While revenue projections for Hims' peptide business are optimistic over the next five to ten years, exceeding $1 billion, near-term growth is expected to be gradual.

Industry experts believe that wider access to certain peptides hinges on the FDA's final rulemaking, which could take approximately a year. There's a possibility for interim market entry through regulatory enforcement discretion, potentially allowing Hims to launch treatments sooner than anticipated.